What are the brand names for the recommended long‑acting bronchodilator (LAMA + LABA) combinations, rescue short‑acting β2‑agonist, and triple‑therapy inhalers for a COPD patient transitioning from as‑needed budesonide?

Brand Names for COPD Inhaler Therapies

For a COPD patient transitioning from as-needed budesonide, the recommended LAMA + LABA dual bronchodilator combinations include Anoro Ellipta (umeclidinium/vilanterol), Bevespi Aerosphere (glycopyrrolate/formoterol), Stiolto Respimat (tiotropium/olodaterol), and Duaklir Pressair (aclidinium/formoterol), with rescue therapy using albuterol (ProAir, Ventolin, Proventil) or levalbuterol (Xopenex), and triple therapy options including Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) and Breztri Aerosphere (budesonide/glycopyrrolate/formoterol). 1

LAMA + LABA Dual Bronchodilator Combinations

The GOLD guidelines strongly recommend LAMA/LABA combinations as first-line therapy for symptomatic COPD patients, particularly those in Groups B and D 1. Available brand names include:

Dry Powder Inhalers (DPI)

• Anoro Ellipta: umeclidinium 62.5 mcg/vilanterol 25 mcg, once daily
• Duaklir Pressair: aclidinium 400 mcg/formoterol 12 mcg, twice daily
• Utibron Neohaler: indacaterol 27.5 mcg/glycopyrrolate 15.6 mcg, twice daily

Metered-Dose Inhalers (MDI)

• Bevespi Aerosphere: glycopyrrolate 9 mcg/formoterol 4.8 mcg, twice daily 2

Soft Mist Inhalers (SMI)

• Stiolto Respimat: tiotropium 2.5 mcg/olodaterol 2.5 mcg, once daily

Recent comparative effectiveness data from 2026 demonstrates that umeclidinium-vilanterol (Anoro Ellipta) was associated with 14% lower hazard of moderate-to-severe exacerbations compared to glycopyrrolate-formoterol (Bevespi) and 3% lower hazard compared to tiotropium-olodaterol (Stiolto), with similar safety profiles across all three agents 3. This suggests Anoro Ellipta may offer marginal clinical advantage, though all LAMA/LABA combinations show therapeutic equivalence in real-world practice 4.

Rescue Short-Acting β2-Agonist Inhalers

All COPD patients require a short-acting bronchodilator for acute symptom relief 1, 5:

• Albuterol (salbutamol): ProAir HFA, ProAir RespiClick, Ventolin HFA, Proventil HFA
• Levalbuterol: Xopenex HFA

These should be used as needed for breakthrough symptoms, not as maintenance therapy. Patients must be counseled that increasing rescue inhaler use signals inadequate disease control requiring treatment escalation 5.

Triple Therapy (LAMA + LABA + ICS) Inhalers

For patients with persistent exacerbations despite LAMA/LABA therapy, escalation to triple therapy is recommended 1:

Single-Inhaler Triple Therapy (SITT)

• Trelegy Ellipta: fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg, once daily
• Breztri Aerosphere: budesonide 160 mcg/glycopyrrolate 9 mcg/formoterol 4.8 mcg, twice daily

A 2025 real-world comparative effectiveness study found that fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) was associated with 12% lower rate of moderate-to-severe exacerbations and 11% lower all-cause mortality at 12 months compared to budesonide/glycopyrrolate/formoterol (Breztri) 6. This mortality benefit is clinically significant and should inform prescribing decisions for high-risk patients.

Open Triple Combinations (Multiple Inhalers)

While single-inhaler triple therapy is preferred, open combinations can be constructed by adding:

• Symbicort (budesonide/formoterol): 160/4.5 mcg or 80/4.5 mcg, twice daily 7
• Advair Diskus (fluticasone propionate/salmeterol): 250/50 mcg or 500/50 mcg, twice daily
• Breo Ellipta (fluticasone furoate/vilanterol): 100/25 mcg or 200/25 mcg, once daily

Plus a separate LAMA inhaler (tiotropium, umeclidinium, glycopyrrolate, or aclidinium).

However, single-inhaler triple therapy demonstrates incremental benefit over multiple-inhaler triple therapy and should be prioritized 8.

Clinical Decision Algorithm

For patients transitioning from as-needed budesonide:

1. Assess exacerbation history and symptom burden to determine GOLD group classification 1

2. If Group B (high symptoms, low exacerbation risk):

   • Initiate LAMA/LABA: Anoro Ellipta preferred based on 2026 comparative data 3
   • Provide rescue albuterol MDI

3. If Group D (high symptoms, high exacerbation risk with ≥2 exacerbations/year or ≥1 hospitalization):

   • Initiate triple therapy: Trelegy Ellipta preferred based on mortality benefit 6
   • Provide rescue albuterol MDI
   • Consider blood eosinophil count: if ≥300 cells/μL, ICS-containing regimen strongly indicated 8

4. If Group C (low symptoms, high exacerbation risk):

   • Initiate LAMA/LABA: Anoro Ellipta or Stiolto Respimat
   • Escalate to triple therapy if exacerbations persist 1

Critical Safety Considerations

ICS-containing regimens (triple therapy) increase pneumonia risk, particularly in patients with FEV1 <50% predicted 1. The number needed to harm is 33 patients for 1 year to cause one pneumonia event, while the number needed to treat is 4 patients for 1 year to prevent one moderate-to-severe exacerbation with triple therapy versus dual bronchodilator therapy 8. This favorable risk-benefit ratio supports triple therapy use in appropriate patients, but clinicians must monitor for respiratory infections.

Device selection matters for adherence and efficacy. DPIs require adequate inspiratory flow (typically >30 L/min), making them unsuitable for patients with severe airflow obstruction or poor inspiratory effort. SMIs and MDIs with spacers are alternatives for these patients 2. Persistent patient education with observed technique assessment is essential regardless of device chosen 2.

Budesonide inhalation suspension is indicated only for asthma in children 12 months to 8 years and is NOT appropriate for COPD management 5. The transition from as-needed budesonide suggests possible prior asthma diagnosis or inappropriate therapy that requires reassessment.